Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recombinant antibodies.

J W Larrick¹, K E Fry

¹Genelabs Inc., Redwood City, CA 94063.

Human Antibodies and Hybridomas

|October 1, 1991

Summary

This summary is machine-generated.

Antibody gene studies revolutionized molecular biology, leading to monoclonal antibodies and recombinant DNA techniques. These advancements enable the creation of engineered antibodies with vast pharmaceutical and industrial applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Contrasting effects of Na+, K+-ATPase activation on seizure activity in acute versus chronic models.

Neuroscience·2015

Same author

Clinical trial of a plant-derived antibody on recolonization of mutans streptococci.

Caries research·2005

Same author

Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.

Clinical immunology (Orlando, Fla.)·2001

Same author

Production of secretory IgA antibodies in plants.

Biomolecular engineering·2001

Same author

Producing proteins in transgenic plants and animals.

Current opinion in biotechnology·2001

Same author

Interaction of CAP18-derived peptides with membranes made from endotoxins or phospholipids.

Biophysical journal·2001

Same journal

Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.

Human antibodies and hybridomas·1996

Same journal

Anti-gp210 antibodies in sera of patients with primary biliary cirrhosis. Identification of a 64 kD fragment of gp210 as a major epitope.

Human antibodies and hybridomas·1996

Same journal

Immunogenetics of human IgE.

Human antibodies and hybridomas·1996

Same journal

Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).

Human antibodies and hybridomas·1996

Same journal

A comparison of the performance in vitro of precision cut tissue slices and suspensions of human spleen with special reference to immunoglobulin and cytokine production.

Human antibodies and hybridomas·1996

Same journal

Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice.

Human antibodies and hybridomas·1996

See all related articles

Area of Science:

Molecular Biology
Immunology
Biotechnology

Background:

Antibody gene research has driven fundamental discoveries in eukaryotic gene structure and function.
Key examples include mRNA splicing and gene rearrangement for antibody diversity.
Cell fusion enabled monoclonal antibody production, widely used in life sciences.

Purpose of the Study:

To review advances in antibody gene manipulation using recombinant DNA techniques.
To highlight the advantages of recombinant methods over traditional hybridoma technology.
To discuss the potential applications of engineered antibodies in various fields.

Main Methods:

Recombinant DNA techniques for antibody gene manipulation.
Humanization of rodent monoclonal antibodies and isotype switching.

Related Experiment Videos

Expression of recombinant monoclonal antibodies (rMAb) in prokaryotic and eukaryotic hosts.

Development of in vitro recombinatorial antibody libraries.

Main Results:

Recombinant DNA techniques offer advantages over somatic cell hybridization.
Engineered antibodies can be "humanized" and have altered isotypes.
Recombinant monoclonal antibodies (rMAb) and fragments are produced efficiently in various hosts.
Expression in plants and large-scale systems suggests cost-effective rMAb production.
In vitro generation of high-affinity antibodies is achievable.

Conclusions:

Recombinant DNA technology has transformed antibody engineering.
Engineered antibodies possess significant pharmaceutical and industrial potential.
Advancements facilitate the creation of novel antibody-based therapeutics and tools.